Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center

Mary R. Welch, Antonio Omuro, Lisa M. Deangelis

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Up to 20 of all primary CNS lymphoma (PCNLS) patients are aged 80 years or older, yet data are limited on how best to treat this rapidly growing population. Despite demographic pressures and the proven efficacy of methotrexate (MTX)-based regimens, automatic de-escalation of care based on age is standard practice outside of tertiary care centers. We performed a retrospective review of all PCNSL patients aged 80 years or older treated at Memorial Sloan-Kettering Cancer Center from 1993 to 2011. Demographic and clinical variables were evaluated as predictors of survival by multivariate analysis. Twenty-three of 24 patients were treated with chemotherapy (92 with high-dose MTX, typically in combination with vincristine and procarbazine). One patient received ocular radiation alone for disease limited to the eyes. Response to treatment was noted in 62.5 of patients; 9 (37.5) had refractory disease. Median overall survival was 7.9 months (95 confidence interval [CI]: 5.853), and median progression-free survival was 6.5 months (95 CI: 4.429.5). Two-year survival rate was 33; 3-year survival rate was 17. Three patients lived more than 4 years postdiagnosis. Most patients tolerated therapy well, and despite low baseline creatinine clearance, no significant renal toxicity was noted. Response status and deep brain involvement were identified as the most important predictors of survival. Multidrug regimens containing high-dose MTX are feasible and efficacious among the oldest patients, particularly those who achieve a complete response by their fifth treatment cycle. Aggressive therapy should be offered to select patients irrespective of advanced age.

Original languageEnglish (US)
Pages (from-to)1304-1311
Number of pages8
JournalNeuro-Oncology
Volume14
Issue number10
DOIs
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

Lymphoma
Neoplasms
Methotrexate
Survival Rate
Demography
Confidence Intervals
Procarbazine
Survival
Vincristine
Therapeutics
Survival Analysis
Tertiary Care Centers
Disease-Free Survival
Creatinine
Multivariate Analysis
Radiation
Kidney
Pressure
Drug Therapy
Brain

Keywords

  • chemotherapy
  • elderly
  • primary central nervous system lymphoma
  • quality of life

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. / Welch, Mary R.; Omuro, Antonio; Deangelis, Lisa M.

In: Neuro-Oncology, Vol. 14, No. 10, 10.2012, p. 1304-1311.

Research output: Contribution to journalArticle

Welch, Mary R. ; Omuro, Antonio ; Deangelis, Lisa M. / Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. In: Neuro-Oncology. 2012 ; Vol. 14, No. 10. pp. 1304-1311.
@article{68699bdf841e4110826924ce1a380a54,
title = "Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center",
abstract = "Up to 20 of all primary CNS lymphoma (PCNLS) patients are aged 80 years or older, yet data are limited on how best to treat this rapidly growing population. Despite demographic pressures and the proven efficacy of methotrexate (MTX)-based regimens, automatic de-escalation of care based on age is standard practice outside of tertiary care centers. We performed a retrospective review of all PCNSL patients aged 80 years or older treated at Memorial Sloan-Kettering Cancer Center from 1993 to 2011. Demographic and clinical variables were evaluated as predictors of survival by multivariate analysis. Twenty-three of 24 patients were treated with chemotherapy (92 with high-dose MTX, typically in combination with vincristine and procarbazine). One patient received ocular radiation alone for disease limited to the eyes. Response to treatment was noted in 62.5 of patients; 9 (37.5) had refractory disease. Median overall survival was 7.9 months (95 confidence interval [CI]: 5.853), and median progression-free survival was 6.5 months (95 CI: 4.429.5). Two-year survival rate was 33; 3-year survival rate was 17. Three patients lived more than 4 years postdiagnosis. Most patients tolerated therapy well, and despite low baseline creatinine clearance, no significant renal toxicity was noted. Response status and deep brain involvement were identified as the most important predictors of survival. Multidrug regimens containing high-dose MTX are feasible and efficacious among the oldest patients, particularly those who achieve a complete response by their fifth treatment cycle. Aggressive therapy should be offered to select patients irrespective of advanced age.",
keywords = "chemotherapy, elderly, primary central nervous system lymphoma, quality of life",
author = "Welch, {Mary R.} and Antonio Omuro and Deangelis, {Lisa M.}",
year = "2012",
month = "10",
doi = "10.1093/neuonc/nos207",
language = "English (US)",
volume = "14",
pages = "1304--1311",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center

AU - Welch, Mary R.

AU - Omuro, Antonio

AU - Deangelis, Lisa M.

PY - 2012/10

Y1 - 2012/10

N2 - Up to 20 of all primary CNS lymphoma (PCNLS) patients are aged 80 years or older, yet data are limited on how best to treat this rapidly growing population. Despite demographic pressures and the proven efficacy of methotrexate (MTX)-based regimens, automatic de-escalation of care based on age is standard practice outside of tertiary care centers. We performed a retrospective review of all PCNSL patients aged 80 years or older treated at Memorial Sloan-Kettering Cancer Center from 1993 to 2011. Demographic and clinical variables were evaluated as predictors of survival by multivariate analysis. Twenty-three of 24 patients were treated with chemotherapy (92 with high-dose MTX, typically in combination with vincristine and procarbazine). One patient received ocular radiation alone for disease limited to the eyes. Response to treatment was noted in 62.5 of patients; 9 (37.5) had refractory disease. Median overall survival was 7.9 months (95 confidence interval [CI]: 5.853), and median progression-free survival was 6.5 months (95 CI: 4.429.5). Two-year survival rate was 33; 3-year survival rate was 17. Three patients lived more than 4 years postdiagnosis. Most patients tolerated therapy well, and despite low baseline creatinine clearance, no significant renal toxicity was noted. Response status and deep brain involvement were identified as the most important predictors of survival. Multidrug regimens containing high-dose MTX are feasible and efficacious among the oldest patients, particularly those who achieve a complete response by their fifth treatment cycle. Aggressive therapy should be offered to select patients irrespective of advanced age.

AB - Up to 20 of all primary CNS lymphoma (PCNLS) patients are aged 80 years or older, yet data are limited on how best to treat this rapidly growing population. Despite demographic pressures and the proven efficacy of methotrexate (MTX)-based regimens, automatic de-escalation of care based on age is standard practice outside of tertiary care centers. We performed a retrospective review of all PCNSL patients aged 80 years or older treated at Memorial Sloan-Kettering Cancer Center from 1993 to 2011. Demographic and clinical variables were evaluated as predictors of survival by multivariate analysis. Twenty-three of 24 patients were treated with chemotherapy (92 with high-dose MTX, typically in combination with vincristine and procarbazine). One patient received ocular radiation alone for disease limited to the eyes. Response to treatment was noted in 62.5 of patients; 9 (37.5) had refractory disease. Median overall survival was 7.9 months (95 confidence interval [CI]: 5.853), and median progression-free survival was 6.5 months (95 CI: 4.429.5). Two-year survival rate was 33; 3-year survival rate was 17. Three patients lived more than 4 years postdiagnosis. Most patients tolerated therapy well, and despite low baseline creatinine clearance, no significant renal toxicity was noted. Response status and deep brain involvement were identified as the most important predictors of survival. Multidrug regimens containing high-dose MTX are feasible and efficacious among the oldest patients, particularly those who achieve a complete response by their fifth treatment cycle. Aggressive therapy should be offered to select patients irrespective of advanced age.

KW - chemotherapy

KW - elderly

KW - primary central nervous system lymphoma

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=84866925399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866925399&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nos207

DO - 10.1093/neuonc/nos207

M3 - Article

C2 - 22952196

AN - SCOPUS:84866925399

VL - 14

SP - 1304

EP - 1311

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 10

ER -